Results 151 to 160 of about 70,999 (292)

High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+ is a recently approved serum‐based test combining two biomarkers (miR‐34a‐5p and YKL‐40) to identify at‐risk MASH (i.e., MASH and significant fibrosis). Objective To assess the prevalence of at‐risk MASH by NIS2+ in individuals from primary care
Srilaxmi Kalavalapalli   +12 more
wiley   +1 more source

Guidelines for Elastography [PDF]

open access: yesMedical Ultrasonography, 2013
Alina, Popescu, Ioan, Sporea
openaire   +2 more sources

Bringing Gene Therapy Into Real World Clinical Practice

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach   +2 more
wiley   +1 more source

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh   +5 more
wiley   +1 more source

Machine Learning Approach Enables Highly Accurate Identification of At‐Risk Metabolic Dysfunction‐Associated Steatohepatitis

open access: yesHepatology Research, EarlyView.
ABSTRACT Aim At‐risk metabolic dysfunction‐associated steatohepatitis (MASH), characterized by significant activity and fibrosis, increases the risk of liver complications. Liver stiffness measurement (LSM), commonly used to detect significant fibrosis, has limitations in terms of accessibility and performance in certain populations.
Masaya Sato   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy